2019
DOI: 10.7124/bc.00099f
|View full text |Cite
|
Sign up to set email alerts
|

Hit identification of FGFR1 inhibitors using receptor-based virtual screening

Abstract: Aim. To identify novel FGFR1 inhibitors using the virtual screening approach. Methods. Virtual screening of a small organic compounds library was performed by molecular docking using the Autodock 4.2.6 program package. The compounds activity was determined by in vitro biochemical tests using γ-32P ATP. Results. In vitro experiments demonstrated that 18 compounds belonging to three chemical classes had an inhibitory activity against FGFR1 with IC50 values in the range from 1.8 to 71 μM. Conclusions. Several FGF… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2023
2023
2023
2023

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 17 publications
0
1
0
Order By: Relevance
“…Replacing the cyclohexyl side chain with an open ester one (R1) and a methyl group (R2) was carried out to further explore the effect of this replacement on biological activity and compare results between a cyclic side chain and the open one. Furthermore, sulfonamides had been previously incorporated in compounds resulting in promising anticancer activity, especially kinase inhibition profiles [ 18 , 19 , 20 ]. Accordingly, it prompted our interest to link the coplanar cyclic structure of thienopyrimidine with different substituted sulfonamide groups which were incorporated in the thienopyrimidine core at position 4 to afford two novel series of thienopyrimidine–sulfonamide hybrids “series a from 1a – 4a ( i – iii )” and “series b from 1b – 4b ( i – iii )”, aiming to explore their biological anticancer and apoptotic activities ( Figure 1 ).…”
Section: Introductionmentioning
confidence: 99%
“…Replacing the cyclohexyl side chain with an open ester one (R1) and a methyl group (R2) was carried out to further explore the effect of this replacement on biological activity and compare results between a cyclic side chain and the open one. Furthermore, sulfonamides had been previously incorporated in compounds resulting in promising anticancer activity, especially kinase inhibition profiles [ 18 , 19 , 20 ]. Accordingly, it prompted our interest to link the coplanar cyclic structure of thienopyrimidine with different substituted sulfonamide groups which were incorporated in the thienopyrimidine core at position 4 to afford two novel series of thienopyrimidine–sulfonamide hybrids “series a from 1a – 4a ( i – iii )” and “series b from 1b – 4b ( i – iii )”, aiming to explore their biological anticancer and apoptotic activities ( Figure 1 ).…”
Section: Introductionmentioning
confidence: 99%